Furthermore, most interestingly, recent studies, taking advantage of newly developed, non-commercially available reagents, clearly indicate that IDO protein expression is detectable in tumor cells in 20% of clinical PCa specimens (55). This evidence concerns the gene IDO1 and posterior cortical atrophy.